#PSMA+BCR
That is how @theNCI #BCR Working Group unanimously agreed to define pts w/PSMA findings & neg CT/bone scan after definitive tx
Retains all that is known about #BCR while drawing a distinction vs. mCSPC
More than semantics for #ProstateCancer pts & clinicians
@ascocancer.bsky.social
That is how @theNCI #BCR Working Group unanimously agreed to define pts w/PSMA findings & neg CT/bone scan after definitive tx
Retains all that is known about #BCR while drawing a distinction vs. mCSPC
More than semantics for #ProstateCancer pts & clinicians
@ascocancer.bsky.social
October 28, 2025 at 3:05 PM
#PSMA+BCR
That is how @theNCI #BCR Working Group unanimously agreed to define pts w/PSMA findings & neg CT/bone scan after definitive tx
Retains all that is known about #BCR while drawing a distinction vs. mCSPC
More than semantics for #ProstateCancer pts & clinicians
@ascocancer.bsky.social
That is how @theNCI #BCR Working Group unanimously agreed to define pts w/PSMA findings & neg CT/bone scan after definitive tx
Retains all that is known about #BCR while drawing a distinction vs. mCSPC
More than semantics for #ProstateCancer pts & clinicians
@ascocancer.bsky.social
Rae. Me too, so happy for him! Though years of faithfulness to testing and checking PSA, a biopsy, MRI, my latest PSMA PET Test results for me are grim. Stage 4A. 30-60% 5 year survivability. Androgen deprivation soon is the plan, then a little while into that 22 to 44 rounds of radiation.
October 27, 2025 at 2:54 AM
Rae. Me too, so happy for him! Though years of faithfulness to testing and checking PSA, a biopsy, MRI, my latest PSMA PET Test results for me are grim. Stage 4A. 30-60% 5 year survivability. Androgen deprivation soon is the plan, then a little while into that 22 to 44 rounds of radiation.
#ESMO25: 177Lu-PSMA-617 with ADT plus ARPI showed PFS benefit in hormone-sensitive #ProstateCancer (#HSPC) but no improvement seen with 177Lu-PSMA-617 vs docetaxel in castration-resistant prostate cancer (#mCRPC) after ARPI.
#ESMODailyReporter ➡️ https://ow.ly/2C0e50XeAoj
#ESMODailyReporter ➡️ https://ow.ly/2C0e50XeAoj
October 19, 2025 at 3:45 PM
#ESMO25: 177Lu-PSMA-617 with ADT plus ARPI showed PFS benefit in hormone-sensitive #ProstateCancer (#HSPC) but no improvement seen with 177Lu-PSMA-617 vs docetaxel in castration-resistant prostate cancer (#mCRPC) after ARPI.
#ESMODailyReporter ➡️ https://ow.ly/2C0e50XeAoj
#ESMODailyReporter ➡️ https://ow.ly/2C0e50XeAoj
⚛️ Radioligand therapeutics at #ESMO25
📌 Latest data: GEP-NETs, mCRPC, oligometastatic PCa
📌 Theranostics, PSMA & lutetium, scaling up delivery
📅 18 Oct | 16:30–18:00 | CityCube A
📅 19 Oct | 12:00–12:50 | Hall 7.1c
🔗 buff.ly/yWm5Qdf
📌 Latest data: GEP-NETs, mCRPC, oligometastatic PCa
📌 Theranostics, PSMA & lutetium, scaling up delivery
📅 18 Oct | 16:30–18:00 | CityCube A
📅 19 Oct | 12:00–12:50 | Hall 7.1c
🔗 buff.ly/yWm5Qdf
October 17, 2025 at 4:06 PM
⚛️ Radioligand therapeutics at #ESMO25
📌 Latest data: GEP-NETs, mCRPC, oligometastatic PCa
📌 Theranostics, PSMA & lutetium, scaling up delivery
📅 18 Oct | 16:30–18:00 | CityCube A
📅 19 Oct | 12:00–12:50 | Hall 7.1c
🔗 buff.ly/yWm5Qdf
📌 Latest data: GEP-NETs, mCRPC, oligometastatic PCa
📌 Theranostics, PSMA & lutetium, scaling up delivery
📅 18 Oct | 16:30–18:00 | CityCube A
📅 19 Oct | 12:00–12:50 | Hall 7.1c
🔗 buff.ly/yWm5Qdf
🌎Supporting the @fao.org Port State Measure Agreement #PSMA training at our premises & Coordination Centre in Vigo.
We presented EFCA cooperative model for #FisheriesControl, with a special focus on our projects in Africa, to participants from 15 countries.
Training together to fight #IUUfishing.🎣
We presented EFCA cooperative model for #FisheriesControl, with a special focus on our projects in Africa, to participants from 15 countries.
Training together to fight #IUUfishing.🎣
October 15, 2025 at 2:25 PM
🌎Supporting the @fao.org Port State Measure Agreement #PSMA training at our premises & Coordination Centre in Vigo.
We presented EFCA cooperative model for #FisheriesControl, with a special focus on our projects in Africa, to participants from 15 countries.
Training together to fight #IUUfishing.🎣
We presented EFCA cooperative model for #FisheriesControl, with a special focus on our projects in Africa, to participants from 15 countries.
Training together to fight #IUUfishing.🎣
As #ESMO25 brings new data on #PSMA it may be time to consider what happens when you target a surface antigen in cancer. How will that impact diagnostic sensitivity of that target?
#PSMAdark
#ProstateCancer #theranostics
Dr Abel et al
@natrevurol.nature.com @ascocancer.bsky.social
rdcu.be/eKNQe
#PSMAdark
#ProstateCancer #theranostics
Dr Abel et al
@natrevurol.nature.com @ascocancer.bsky.social
rdcu.be/eKNQe
October 14, 2025 at 2:11 PM
As #ESMO25 brings new data on #PSMA it may be time to consider what happens when you target a surface antigen in cancer. How will that impact diagnostic sensitivity of that target?
#PSMAdark
#ProstateCancer #theranostics
Dr Abel et al
@natrevurol.nature.com @ascocancer.bsky.social
rdcu.be/eKNQe
#PSMAdark
#ProstateCancer #theranostics
Dr Abel et al
@natrevurol.nature.com @ascocancer.bsky.social
rdcu.be/eKNQe
The introduction of PSMA PET has fundamentally altered the imaging landscape for prostate cancer, prompting a critical debate over the current and future utility of conventional bone scintigraphy. A new point/counterpoint from AJR explores this topic.
October 6, 2025 at 4:32 PM
The introduction of PSMA PET has fundamentally altered the imaging landscape for prostate cancer, prompting a critical debate over the current and future utility of conventional bone scintigraphy. A new point/counterpoint from AJR explores this topic.
“Men with aggressive prostate cancer..being treated with a groundbreaking drug have been told the therapy is no longer available..Lutetium PSMA was compounded locally, after pharmaceutical giant took legal action, public hospitals say they can not offer the treatment”
www.abc.net.au/news/2025-10...
www.abc.net.au/news/2025-10...
Cancer patients told treatment no longer available at public hospitals
Men with aggressive prostate cancer who were being treated with a groundbreaking drug have been told the therapy is no longer available at public hospitals.
www.abc.net.au
October 1, 2025 at 12:23 AM
“Men with aggressive prostate cancer..being treated with a groundbreaking drug have been told the therapy is no longer available..Lutetium PSMA was compounded locally, after pharmaceutical giant took legal action, public hospitals say they can not offer the treatment”
www.abc.net.au/news/2025-10...
www.abc.net.au/news/2025-10...
@fao.org welcomes the @wto.org Agreement on Fisheries Subsidies.
“This agreement is very positive for the sustainability of fisheries resources, which we all depend on,” said @manufao.bsky.social.
www.fao.org/newsroom/det...
#PSMA #FightIUUFishing
“This agreement is very positive for the sustainability of fisheries resources, which we all depend on,” said @manufao.bsky.social.
www.fao.org/newsroom/det...
#PSMA #FightIUUFishing
September 15, 2025 at 2:27 PM
@fao.org welcomes the @wto.org Agreement on Fisheries Subsidies.
“This agreement is very positive for the sustainability of fisheries resources, which we all depend on,” said @manufao.bsky.social.
www.fao.org/newsroom/det...
#PSMA #FightIUUFishing
“This agreement is very positive for the sustainability of fisheries resources, which we all depend on,” said @manufao.bsky.social.
www.fao.org/newsroom/det...
#PSMA #FightIUUFishing
January 17, 2025 at 12:11 AM
A quick reminder: if you know young creatives who’d love to be in the chance of winning the Portico Art of the Book Award, entries need to be in by midnight, Fri 14th Feb 2025!
Find out how to enter: www.theportico.org.uk/portico-sadie-massey-awards
Or email psma@theportico.org.uk
Best of luck!
Find out how to enter: www.theportico.org.uk/portico-sadie-massey-awards
Or email psma@theportico.org.uk
Best of luck!
Portico Sadie Massey Awards — The Portico Library
www.theportico.org.uk
February 14, 2025 at 10:05 AM
A quick reminder: if you know young creatives who’d love to be in the chance of winning the Portico Art of the Book Award, entries need to be in by midnight, Fri 14th Feb 2025!
Find out how to enter: www.theportico.org.uk/portico-sadie-massey-awards
Or email psma@theportico.org.uk
Best of luck!
Find out how to enter: www.theportico.org.uk/portico-sadie-massey-awards
Or email psma@theportico.org.uk
Best of luck!
"addition of [177Lu] Lu-PSMA-617 to enzalutamide was associated with improved survival and some aspects of HRQOL in patients with high-risk metastatic castration-resistant prostate cancer." #gu25
www.thelancet.com/journals/lan...
www.thelancet.com/journals/lan...
Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicen...
The addition of [177Lu] Lu-PSMA-617 to enzalutamide was associated with improved survival
and some aspects of HRQOL in patients with high-risk metastatic castration-resistant
prostate cancer. Our find...
www.thelancet.com
February 14, 2025 at 3:01 AM
"addition of [177Lu] Lu-PSMA-617 to enzalutamide was associated with improved survival and some aspects of HRQOL in patients with high-risk metastatic castration-resistant prostate cancer." #gu25
www.thelancet.com/journals/lan...
www.thelancet.com/journals/lan...
Early PSMA-based RLT shows promise for hormone-sensitive prostate cancer, especially in early stages with less cancer and healthier organs. This may enhance treatment effectiveness and allow combining treatments without more side effects.
August 1, 2025 at 6:00 AM
Early PSMA-based RLT shows promise for hormone-sensitive prostate cancer, especially in early stages with less cancer and healthier organs. This may enhance treatment effectiveness and allow combining treatments without more side effects.
Lutetium-177–PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Lutetium-177–PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial - Nature Medicine
In a post-hoc analysis of circulating tumor DNA (ctDNA) features from patients with metastatic prostate cancer treated with [177Lu]Lu–PSMA-617 or cabazitaxel in the randomized phase 2 TheraP trial, lo...
www.nature.com
May 29, 2025 at 12:02 AM
Lutetium-177–PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Why is the Port State Measures Agreement key to #StopIUUFishing?
On the International Day for the fight against #IUUFishing, @fao.org Members share why the #PSMA matters for the ocean, for people, & for a more sustainable future.
#Tonga #Russia & #Libya share their thoughts
👇
#FightIUUFishing
On the International Day for the fight against #IUUFishing, @fao.org Members share why the #PSMA matters for the ocean, for people, & for a more sustainable future.
#Tonga #Russia & #Libya share their thoughts
👇
#FightIUUFishing
June 5, 2025 at 6:53 AM
Why is the Port State Measures Agreement key to #StopIUUFishing?
On the International Day for the fight against #IUUFishing, @fao.org Members share why the #PSMA matters for the ocean, for people, & for a more sustainable future.
#Tonga #Russia & #Libya share their thoughts
👇
#FightIUUFishing
On the International Day for the fight against #IUUFishing, @fao.org Members share why the #PSMA matters for the ocean, for people, & for a more sustainable future.
#Tonga #Russia & #Libya share their thoughts
👇
#FightIUUFishing
Our science at SITC -2 abstracts in the top 150 #Miltenyi #SITC25 #SITC2025 MSLN armored CAR-T (208), PSMA armored CAR-T (228) Spatial proteomics of post Tx sarcoma (243) CD5 CAR-NK (252) BCMA bi-paratopic CAR-T (292) CD276 CAR-T fitness (295) hypoxia expanded NK cells (390) @sitcancer.bsky.social
November 4, 2025 at 8:10 PM
Our science at SITC -2 abstracts in the top 150 #Miltenyi #SITC25 #SITC2025 MSLN armored CAR-T (208), PSMA armored CAR-T (228) Spatial proteomics of post Tx sarcoma (243) CD5 CAR-NK (252) BCMA bi-paratopic CAR-T (292) CD276 CAR-T fitness (295) hypoxia expanded NK cells (390) @sitcancer.bsky.social
« Ponchour j'ai fait ma choline et tout le reste ailleurs mais cet ailleurs me donne un rendez-vous de PSMA trop loin à mon goût alors je viens chez vous. »
a man in a suit and tie is laughing with the word hahaha written on his face
ALT: a man in a suit and tie is laughing with the word hahaha written on his face
media.tenor.com
March 27, 2025 at 10:16 AM
« Ponchour j'ai fait ma choline et tout le reste ailleurs mais cet ailleurs me donne un rendez-vous de PSMA trop loin à mon goût alors je viens chez vous. »
#Theranostics: the future for #prostatecancer treatment is here!! https://youtu.be/8cRfV_mXHyE
Let our nucmed techs Nadine and Caroline guide you through the history of #PSMA radiopharmaceuticals and discuss their potential roles in #dosimetry for personalized #RPTs
Let our nucmed techs Nadine and Caroline guide you through the history of #PSMA radiopharmaceuticals and discuss their potential roles in #dosimetry for personalized #RPTs
January 20, 2025 at 6:09 AM
#Theranostics: the future for #prostatecancer treatment is here!! https://youtu.be/8cRfV_mXHyE
Let our nucmed techs Nadine and Caroline guide you through the history of #PSMA radiopharmaceuticals and discuss their potential roles in #dosimetry for personalized #RPTs
Let our nucmed techs Nadine and Caroline guide you through the history of #PSMA radiopharmaceuticals and discuss their potential roles in #dosimetry for personalized #RPTs
Different PSMA radioligands show varying bladder activity in prostate cancer scans. Furosemide reduces this activity and increases bladder size, improving scan clarity. With furosemide, 18F-rhPSMA-7.3 activity is similar to 18F-PSMA-1007.
June 8, 2025 at 10:00 AM
Different PSMA radioligands show varying bladder activity in prostate cancer scans. Furosemide reduces this activity and increases bladder size, improving scan clarity. With furosemide, 18F-rhPSMA-7.3 activity is similar to 18F-PSMA-1007.
Studies and guidelines show PSMA-PET, especially 68Ga-PSMA-PET, is very specific for prostate cancer. Its sensitivity is limited but better than traditional imaging, especially for high-risk patients. It can't replace extended pelvic lymph node dissection yet.
July 20, 2025 at 6:00 AM
Studies and guidelines show PSMA-PET, especially 68Ga-PSMA-PET, is very specific for prostate cancer. Its sensitivity is limited but better than traditional imaging, especially for high-risk patients. It can't replace extended pelvic lymph node dissection yet.
＼ 関東初導入！ ／前立腺がんの診断にPSMA-PET導入でより正確な診断が可能に！ - PR TIMES
news.google.com/rss/articles/CBMiOmh0dHBzOi8vcHJ0aW1lcy5qcC9tYWluL2h0bWwvcmQvcC8wMDAwMDAwMDQuMDAwMDM2MDQwLmh0bWzSAQA?oc=5
news.google.com/rss/articles/CBMiOmh0dHBzOi8vcHJ0aW1lcy5qcC9tYWluL2h0bWwvcmQvcC8wMDAwMDAwMDQuMDAwMDM2MDQwLmh0bWzSAQA?oc=5
April 1, 2024 at 3:09 PM
＼ 関東初導入！ ／前立腺がんの診断にPSMA-PET導入でより正確な診断が可能に！ - PR TIMES
news.google.com/rss/articles/CBMiOmh0dHBzOi8vcHJ0aW1lcy5qcC9tYWluL2h0bWwvcmQvcC8wMDAwMDAwMDQuMDAwMDM2MDQwLmh0bWzSAQA?oc=5
news.google.com/rss/articles/CBMiOmh0dHBzOi8vcHJ0aW1lcy5qcC9tYWluL2h0bWwvcmQvcC8wMDAwMDAwMDQuMDAwMDM2MDQwLmh0bWzSAQA?oc=5
Just re-read Daniel Nettle's essay "What we talk about when we talk about biology" for my class on cultural evolution. If I had my druthers, it would be read aloud, in its entirely, at the start of every social science conference until they got the message. www.openbookpublishers.com/books/10.116...
September 8, 2024 at 5:56 PM